Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico

References

• Lara A, Rosas M, Pastelín G, et al. Encuesta Nacional de Salud 2000. Hipercolesterolemia e hipertensión arterial en México. Consolidación urbana actual con obesidad, diabetes y tabaquismo. Arch Cardiol Mex 2004;74:231-5
   PubMedGoogle Scholar
• MoH, SINAIS; Mortality Data. http://sinais.salud.gob.mx/mortalidad/tabs/m_005.xls [Last accessed 3 May 2007]
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003;24:1601-10
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• The long-term intervention with pravastatin in ischaemic disease (lipid) study group prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9
   Google Scholar
• Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. 2004;110:227-39
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al.; PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65
   PubMed Web of Science ®Google Scholar
• Gotto, AM. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007;99:718-25
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Mckenney, JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health-Syst Pharm 2005;62:1033-47
   PubMed Web of Science ®Google Scholar
• Carrizal-Madrigal J, Herrera-Cortes A, Lemus-Colunga H. Efecto de la combinación de ezetimiba mas estatinas sobre los lípidos en pacientes mexicanos. Med Int Mex 2007;23:280-5
   Google Scholar
• Davidson, MH, McGarry, T, Bettis, R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34i
   PubMed Web of Science ®Google Scholar
• Bays, HE, Ose, L, Fraser, N. A multicenter randomized double-blind placebo-control factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Therapeut 2004;26:1758-73
   PubMed Web of Science ®Google Scholar
• McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health-Syst Pharm 2005;62:1033-47
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511-28
   PubMed Web of Science ®Google Scholar
• Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and national cholesterol education program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;20:469-78
   Web of Science ®Google Scholar
• No Authors Listed. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;16:2486–97
   Google Scholar
• Grundy SM, Cleeman JI, Merz CNB. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Baessler A, Fischer M, Huf V, et al. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol 2005;101:293-8
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556-63
   PubMed Web of Science ®Google Scholar
• Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9
   PubMed Web of Science ®Google Scholar
• Valuck RJ, Williams SA, MacArthur M, et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003;25:2936-57
   PubMed Web of Science ®Google Scholar
• Hildemann SK, Barho C, Karmann B, et al. Dual cholesterol inhibition with ezetimibe/simvastatin in pretreated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: Prospective observational cohort studies in clinical practice. Curr Med Res Opin 2007;23:713-19
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041-53
   PubMed Web of Science ®Google Scholar
• Goff DC, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA) gender, ethnicity, and coronary artery calcium. Circulation 2006;113:647-56
   PubMed Web of Science ®Google Scholar
• Harley CR, Gandhi SK, Heien H, et al. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother 2008;9:669-76
   PubMed Web of Science ®Google Scholar